ArticleThe international journal of cardiovascular imaging2017
Association between interleukin-6 and the risk of cardiac events measured by coronary computed tomography angiography.
Article in The international journal of cardiovascular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.JACC. Cardiovascular imaging · 2022Trial
- Coronary computed tomography angiography detection of short- and long-term outcomes after heart valve surgery with high risk cardiovascular patients.Bioscience reports · 2018Trial
- The association between plasma inflammatory, oxidant, and antioxidant status with cardiometabolic indices and coronary artery stenosis in participants undergoing coronary angiography: a case-control study.BMC cardiovascular disorders · 2026Article
- Relationship between interleukin-6, coronary artery calcium and risk of heart failure: Insights from MESA.American journal of preventive cardiology · 2025Article
- Platelet-Leukocyte Aggregate and Interleukin-6: An Emerging Perspective on a New Diagnostic and Therapeutic Clue for Acute Coronary Syndrome, A Case-Control Study.Health science reports · 2024Article
- Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention.BMC cardiovascular disorders · 2023Article
- Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment.Life (Basel, Switzerland) · 2023Review
- Acute Changes in Interleukin-6 Level During Four Days of Long-Distance Walking.Journal of inflammation research · 2020Article
- Sudden Cardiac Death (SCD) - risk stratification and prediction with molecular biomarkers.Journal of biomedical science · 2019Review
- Increased glycoprotein acetylation is associated with high cardiac event rates: Analysis using coronary computed tomography angiography.Anatolian journal of cardiology · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) has been found to be a predictor of heart attack. We aimed to investigate the relationship of risk factor IL-6 with extent and severity of the coronary artery disease (CAD) evaluated using coronary computed tomography angiography (CCTA). A total of 303 participants without history of CAD undergoing CCTA were enrolled. Using the model of risk-adjusted Cox proportional-hazards, the association of IL-6 level with major adverse cardiac events (MACE) was detected. The participants were assigned into three study groups based on serum IL-6 level. Compared with those in the lowest tertile, patients with highest IL-6 level displayed higher atherosclerotic burden such as plaque extent defined as prevalence of obstructive CAD and segments with any plaque. After a median 3.0 year follow-up period, we also found that patients with highest IL-6 level experienced higher MACE risk and all-cause death compared with those from the lowest tertile. Among participants without CAD history who underwent CCTA, patients with high level of IL-6 had increased burden of atherosclerosis and higher MACE risk compared to participants of low level of IL-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.